Overview

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Status:
Active, not recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine the effect of combining everolimus and sorafenib in patients with metastatic differentiated thyroid cancer who progressed on sorafenib alone.

Phase:

Phase 2

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania
Thomas Jefferson University

Collaborators:

Bayer
Novartis Pharmaceuticals

Treatments:

Everolimus
Niacinamide
Sirolimus
Sorafenib